One dose of experimental siRNA therapy lowered liver fat in an early trial

An early trial tested CIDEBsiRNA, also known as ALN-CIDEB, in patients with MASLD.

The therapy is a small interfering RNA treatment.

Patients received one dose.

In most patients, liver fat content reached normal levels.

Most also had lower levels of ALT, a liver enzyme.

The findings are early, and the available information does not say what happens next.